More PYC Therapeutics Limited news
PYC Therapeutics LimitedASX: PYC

Successful Efficacy Result on Path to First in Human Studies

Mar 31, 2020 at 11:22 PM EDT · Issued by PYC Therapeutics Limited

Filed with ASX · Mar 31, 2020 at 11:22 PM EDT

On 6ix: 6ix.com/news/successful-efficacy-result-on-path-to-first-in-human-studies

Pyc Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

PYC Therapeutics Limited on 6ix

Story so far

  • Successful Major Milestone - Human Retina in a Dish ModelsOct 9, 2019
  • Phylogicas Technology is Effective in Human CellsAug 6, 2019

Earlier from PYC Therapeutics

  • Investor Presentation - February 2020Feb 23, 2020
  • CEO Appointment and Establishment of US OfficeFeb 12, 2020
  • Expansion Of Drug Development PipelineFeb 2, 2020
  • Appendix 4C - quarterlyJan 31, 2020
  • Quarterly Shareholder UpdateJan 5, 2020

Later from PYC Therapeutics

  • March 2020 Quarterly Activities and Cash Flow ReportApr 29, 2020
  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • Successful Dose Response & Toxicity Studies in Lead ProgramJul 21, 2020
  • June 2020 Quarterly Activity Report and CashflowJul 30, 2020
  • Shareholder Update - Forward View 2020 MilestonesAug 4, 2020
All PYC Therapeutics news releases↗

Follow PYC Therapeutics into a list and get an email when it puts out news.

Follow PYC Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer